The biotech investment community needs to look beyond the existing pools of funding and talent to galvanize biomedical innovation.
Volume 30 Issue 10, October 2012
New data indicating underreporting of federal funding in academic biomedical patents highlight the pressing need for greater transparency under the Bayh-Dole Act.
News & Views
The authors propose that the increasing risk of biopharma investing can be reduced through megafunds that support many biomedical programs and attract investment from large institutions such as pension funds.
Komori et al. show that hepatocytes, pancreatic islets and thymocytes flourish in the mouse lymph node, suggesting that lymph nodes could serve as a transplantation site for cell therapies.
By combining two metabolic labeling techniques, Eichelbaum et al. detect and quantify large numbers of secreted proteins, including low-abundance proteins such as cytokines.
Bacchus et al. describe the first experiments in mammalian cells that distribute complex behavior across several types of engineered cells, thereby mimicking natural multicellular systems.
Frei et al. show that a new tri-functional reagent identifies unknown cell-surface receptors bound by known ligands on living cells.
Careers and Recruitment
In This Issue
The present system for commercializing biomedical research remains woefully inefficient and underpowered. This issue of Nature Biotechnologycollects several articles that describe alternatives to current pathways for clinical translation of academic discovery.